NMN Liposomal
About
About NMN Liposomal
Liposomal NMN (nicotinamide mononucleotide) encapsulates NMN in phospholipid vesicles to improve cellular delivery and bioavailability compared to standard oral NMN. The liposomal formulation is designed to protect NMN from digestive degradation and enhance absorption through the intestinal epithelium and direct cellular uptake. It is marketed as a premium NAD+ precursor supplement with potentially superior pharmacokinetics to standard NMN powder or capsules.
Science
Mechanism of Action
Liposomal encapsulation enables fusion with cell membranes for direct intracellular NMN delivery; NMN is then phosphorylated to NAD+ via NMNAT enzymes, replenishing the NAD+ pool for sirtuin activation, PARP repair activity, and mitochondrial energy metabolism.
Dosing
Typical Protocol
125–500 mg oral daily; liposomal formulations may be effective at lower doses than standard NMN due to enhanced bioavailability.
⚠ Protocol information is for educational purposes only. Dosing must be determined by a licensed physician based on individual health status and goals.
Regulatory
Legal Status in 2026
This compound has completed clinical trials and received formal FDA approval for one or more indications. It can be legally prescribed by licensed physicians, filled at any licensed pharmacy, and may be covered by insurance. Off-label use by physicians is also legal. This is the highest level of regulatory clearance available in the US.
Evidence
Evidence Tier
Evidence primarily from animal studies, cell cultures, or small pilot human trials. Results are promising but have not yet been confirmed in large-scale human RCTs. Effects in humans may differ from animal models.
Find a Verified Provider
See which Vial-verified providers offer NMN Liposomal — with trust scores, legal credentials, and pricing transparency.